Results 111 to 120 of about 25,780 (241)

Phase I and pharmacologic study of topotecan in patients with impaired renal function.

, 1996
PURPOSE To determine the toxicities, pharmacokinetics, and recommended doses of the topoisomerase I inhibitor, topotecan, in patients with varying degrees of renal excretory dysfunction.
A A Forastiere, S O'Reilly, T L Chen, L B Grochow, D S Ettinger, S Sartorius, E K Rowinsky, W Slichenmyer, R C Donehower   +8 more
core   +1 more source

Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside

OncoImmunology, 2018
Despite recent advances in high-risk neuroblastoma therapy, the prognosis for patients remains poor. In addition, many patients suffer from complications related to available therapies that are highly detrimental to their quality of life.
S. Faraj, M. Bahri, S. Fougeray, A. El Roz, J. Fleurence, J. Véziers, M. D. Leclair, E. Thébaud, F. Paris, S. Birklé   +9 more
doaj   +1 more source

Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.

, 1996
PURPOSE To determine the maximum-tolerated systemic exposure (MTSE) and exposure-limiting toxicity of continuous infusion topotecan in children with recurrent acute leukemia.
W E Evans, C B Pratt, S D Baker, W L Furman, C F Stewart, G K Rivera   +5 more
core   +1 more source

Suprachoroidal Injection of Topotecan for Retinoblastoma: A Preclinical Study

Ophthalmology Science
Purpose: To assess whether levels of topotecan that are expected to be therapeutic against retinoblastoma tumors can be achieved within the retina and choroid by suprachoroidal injection (SCI) and to assess toxicity and safety in vivo.
Arun D. Singh, MD, Vishal Raval, MD, Sandeep Kumar, PhD, Anthony Daniels, MD   +3 more
doaj   +1 more source

Factors affecting pharmacokinetic variability of oral topotecan: a population analysis

, 2004
The aim of this study was to characterise the pharmacokinetics of the anticancer agent topotecan, and explore the influence of patient covariates and interoccasion variability on drug disposition.
J Verweij, Bugat, R, A Sparreboom, M Goffinet, R H J Mathijssen, R Bugat, Verweij, Jaap, Loos, Walter, J Fourcade, E Chatelut, F Léger, Goffinet, M, Mathijssen, RHJ; id_orcid, Léger, F, Sparreboom, A, W J Loos, Fourcade, J, Chatelut, E   +17 more
core   +1 more source

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

, 1999
PURPOSE: Topotecan and cyclophosphamide, doxorubicin, and vincristine (CAV) were evaluated in a randomized, multicenter study of patients with small-cell lung cancer (SCLC) who had relapsed at least 60 days after completion of first-line therapy ...
J.P. Kleisbauer, David J. Stewart, Jacqueline B. Krebs, Peter I. Clark, Martin C. Palmer, Frances A. Shepherd, Joan H. Schiller, Graham Ross, Alain Depierre, Stephen R. Lane, Joachim von Pawel, Scott Z. Fields, James Carmichael, Nick G. Chrysson, Richard Gralla   +14 more
core   +1 more source

Proliferation and apoptosis of prostatic cancer cell lines under the influence of Topotecan, Etoposid, Estramustinphosphat and Docetaxel

, 2011
Die vorliegende Arbeit untersucht die Effekte der Zytostatika Topotecan, Etoposid, Docetaxel und Estramustinphopat auf die Hemmung der Zellproliferation und die Induktion von Apoptose bei den Prostatakarzinomzelllinien LNCaP, DU-145 und PC-3.
Adam, Meike
core  

FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11

Acta Pharmacologica Sinica, 2021
Yan-Ping Yin, Li-ying Ma, Guoping Cao, Jing-han Hua, Xiaotong Lv, Wenchu Lin   +5 more
semanticscholar   +1 more source

Topotecan [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

A review of topotecan in combination chemotherapy for advanced cervical cancer

, 2008
Minoo Robati, David Holtz, Charles J DuntonDepartment of Obstetrics and Gynecology, Main Line Gynecologic Oncology, Lankenau Hospital, Wynnewood, PA, USAAbstract: Treatment of advanced, recurrent or persistent cervical cancer includes radiotherapy and ...
David Holtz, Minoo Robati, Charles J Dunton   +2 more
core